Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma

Dwayne Collier, Mark S. Soloway

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The suggested activity of doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and 5- fluorouracil as single agents in the treatment of advanced prostate andlor transitional cell carcinoma led us to examine the response to these drugs used in combination. Combination chemotherapy has the theoretical advantages of additive antitumor effect without additive toxicity to the host. One of 8 patients with Stage D, endocrine unresponsive prostatic adenocarcinoma achieved an objective response. There were five stable and one subjective responses. Only l patient showed progression during the initial six-week trial. Two of 3 patients with transitional cell carcinoma had an objective response. This three-drug combination was well tolerated by elderly patients and on the basis of this small series further trials are warranted.

Original languageEnglish
Pages (from-to)459-464
Number of pages6
JournalUrology
Volume8
Issue number5
DOIs
StatePublished - Jan 1 1976
Externally publishedYes

Fingerprint

Transitional Cell Carcinoma
Fluorouracil
Doxorubicin
Cyclophosphamide
Prostate
Drug Combinations
Combination Drug Therapy
Adenocarcinoma
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma. / Collier, Dwayne; Soloway, Mark S.

In: Urology, Vol. 8, No. 5, 01.01.1976, p. 459-464.

Research output: Contribution to journalArticle

@article{e2237447872b4cb6af882394b08b282d,
title = "Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma",
abstract = "The suggested activity of doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and 5- fluorouracil as single agents in the treatment of advanced prostate andlor transitional cell carcinoma led us to examine the response to these drugs used in combination. Combination chemotherapy has the theoretical advantages of additive antitumor effect without additive toxicity to the host. One of 8 patients with Stage D, endocrine unresponsive prostatic adenocarcinoma achieved an objective response. There were five stable and one subjective responses. Only l patient showed progression during the initial six-week trial. Two of 3 patients with transitional cell carcinoma had an objective response. This three-drug combination was well tolerated by elderly patients and on the basis of this small series further trials are warranted.",
author = "Dwayne Collier and Soloway, {Mark S.}",
year = "1976",
month = "1",
day = "1",
doi = "10.1016/0090-4295(76)90275-2",
language = "English",
volume = "8",
pages = "459--464",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma

AU - Collier, Dwayne

AU - Soloway, Mark S.

PY - 1976/1/1

Y1 - 1976/1/1

N2 - The suggested activity of doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and 5- fluorouracil as single agents in the treatment of advanced prostate andlor transitional cell carcinoma led us to examine the response to these drugs used in combination. Combination chemotherapy has the theoretical advantages of additive antitumor effect without additive toxicity to the host. One of 8 patients with Stage D, endocrine unresponsive prostatic adenocarcinoma achieved an objective response. There were five stable and one subjective responses. Only l patient showed progression during the initial six-week trial. Two of 3 patients with transitional cell carcinoma had an objective response. This three-drug combination was well tolerated by elderly patients and on the basis of this small series further trials are warranted.

AB - The suggested activity of doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and 5- fluorouracil as single agents in the treatment of advanced prostate andlor transitional cell carcinoma led us to examine the response to these drugs used in combination. Combination chemotherapy has the theoretical advantages of additive antitumor effect without additive toxicity to the host. One of 8 patients with Stage D, endocrine unresponsive prostatic adenocarcinoma achieved an objective response. There were five stable and one subjective responses. Only l patient showed progression during the initial six-week trial. Two of 3 patients with transitional cell carcinoma had an objective response. This three-drug combination was well tolerated by elderly patients and on the basis of this small series further trials are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0017094626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017094626&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(76)90275-2

DO - 10.1016/0090-4295(76)90275-2

M3 - Article

C2 - 982733

AN - SCOPUS:0017094626

VL - 8

SP - 459

EP - 464

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -